If you are interested in learning more about the STOP-HCC clinical trial, please contact your doctor.

The purpose of the STOP-HCC trial is to determine if TheraSphere® treatment prior to standard-of-care sorafenib therapy improves survival time and is safe.27,28

Eligible participants for this trial are patients with inoperable hepatocellular carcinoma (HCC) for whom standard-of-care therapy with sorafenib is planned.

The trial will involve approximately 400 patients at up to 40 sites worldwide, including North America and Europe.27,28

Principal Investigator:
  • Riad Salem, MD   Northwestern University, Chicago, US